NGM Biopharmaceuticals Inc (NGM)

NGM Biopharmaceuticals Financial Statements


NGM Biopharmaceuticals Financial Overview

NGM Biopharmaceuticals's market cap is currently ―. The company's EPS TTM is $-1.725; its P/E ratio is -7.34; NGM Biopharmaceuticals is scheduled to report earnings on November 16, 2022, and the estimated EPS forecast is $-0.61. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Mar 22Dec 21Sep 21Jun 21
Income Statement
Total Revenue$ 8.29M$ 20.95M$ 20.96M$ 18.57M$ 16.77M
Gross Profit$ ―$ ―$ ―$ ―$ ―
EBIT$ -47.07M$ -32.58M$ -27.22M$ -29.01M$ -36.62M
EBITDA$ -45.67M$ -31.15M$ -25.75M$ -27.51M$ -35.06M
Net Income Common Stockholders$ -46.52M$ -32.45M$ -27.23M$ -28.86M$ -36.69M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 287.95M$ 295.16M$ 297.81M$ 329.83M$ 366.25M
Total Assets$ 337.37M$ 359.77M$ 402.39M$ 415.86M$ 423.01M
Total Debt$ 5.08M$ 7.90M$ 9.30M$ 5.38M$ 0.00
Net Debt$ -282.87M$ -287.25M$ -288.51M$ -324.45M$ -366.25M
Total Liabilities$ 45.29M$ 48.64M$ 66.74M$ 61.82M$ 49.94M
Stockholders Equity$ 276.70M$ 280.04M$ 292.08M$ 311.14M$ 335.65M
Cash Flow
Free Cash Flow$ -50.97M$ -36.02M$ -18.47M$ -9.55M$ -24.50M
Operating Cash Flow$ -50.15M$ -35.74M$ -18.34M$ -9.36M$ -23.31M
Investing Cash Flow$ -15.97M$ -6.85M$ 21.93M$ 52.30M$ -28.72M
Financing Cash Flow$ 19.62M$ 668.00K$ 2.38M$ 3.48M$ 3.32M
Currency in USD

NGM Biopharmaceuticals Earnings and Revenue History

NGM Biopharmaceuticals Debt to Assets

NGM Biopharmaceuticals Cash Flow

NGM Biopharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis